Diabetes Care, Vol 22, Issue 6 908-912, Copyright © 1999 by American Diabetes Association

ARTICLES

Effect of troglitazone on body fat distribution in type 2 diabetic patients

Y Mori, Y Murakawa, K Okada, H Horikoshi, J Yokoyama, N Tajima and Y Ikeda
Department of Internal Medicine, National Higashi-Utsunomiya Hospital, Tochigi, Japan.

OBJECTIVE: Troglitazone was recently reported to specifically promote the differentiation of pre-adipocytes into adipocytes in vitro in subcutaneous fat only, indicating a relation to insulin-resistance-improving action of troglitazone. To expand on this finding, we investigated at the clinical level how long-term administration of troglitazone influences the body fat distribution in type 2 diabetic patients. RESEARCH DESIGN AND METHODS: Troglitazone (400 mg/day) was administered for 6 months to 30 type 2 diabetic patients whose glycemic control was poor. A total of 18 patients received diet therapy alone (in the single-treatment group, BMI 26.0 +/- 4.6, HbA1c 8.2 +/- 1.7%), and 12 patients concomitantly received glibenclamide (1.25-7.5 mg/day) (in the concomitant sulfonylurea group, BMI 25.4 +/- 4.7, HbA1c 9.2 +/- 1.2%). BMI, HbA1c, serum lipid level, and body fat distribution, which were determined by computed tomography (CT) scan at the umbilical level, were measured and compared before and after troglitazone treatment. RESULTS: During the 6-month troglitazone treatment, HbA1c levels decreased and BMI increased in both groups. As for body fat distribution in the single-treatment group, visceral fat area (VFA) decreased (from 118.3 +/- 54.3 to 101.1 +/- 50.8 cm2; P < 0.001), and subcutaneous fat area (SFA) increased (from 189.7 +/- 93.3 to 221.6 +/- 101.6 cm2; P < 0.001), resulting in a decrease in visceral/subcutaneous (V/S) ratio (from 0.74 +/- 0.48 to 0.50 +/- 0.32; P < 0.001). In the concomitant sulfonylurea group, VFA was unchanged (from 108.1 +/- 53.5 to 112.5 +/- 59.9 cm2), while SFA increased (from 144.6 +/- 122.0 to 180.5 +/- 143.5 cm2; P < 0.01), thereby decreasing the V/S ratio (from 0.91 +/- 0.46 to 0.77 +/- 0.44; P < 0.01). The serum triglyceride level and the area under glucose curve during the 75-g oral glucose tolerance test decreased significantly in the single-treatment group. CONCLUSIONS: According to our data, troglitazone appears to promote fat accumulation in the subcutaneous adipose tissue rather than in the visceral adipose tissue in mildly obese Japanese people with type 2 diabetes. This shift of energy accumulation from the visceral to subcutaneous adipose tissue may greatly contribute to the troglitazone-mediated amelioration of insulin resistance.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Jensterle, A. Janez, B. Mlinar, J. Marc, J. Prezelj, and M. Pfeifer Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome. Eur. J. Endocrinol., June 1, 2008; 158(6): 793 - 801. [Abstract] [Full Text] [PDF]

				J. Y. Park, A. Y. Chong, E. K. Cochran, D. E. Kleiner, M. J. Haller, D. A. Schatz, and P. Gorden Type 1 Diabetes Associated with Acquired Generalized Lipodystrophy and Insulin Resistance: The Effect of Long-Term Leptin Therapy J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 26 - 31. [Abstract] [Full Text] [PDF]

				S.-K. Kim, K.-Y. Hur, H.-J. Kim, W.-S. Shim, C.-W. Ahn, S.-W. Park, Y.-W. Cho, S.-K. Lim, H.-C. Lee, and B.-S. Cha The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment Eur. J. Endocrinol., August 1, 2007; 157(2): 167 - 174. [Abstract] [Full Text] [PDF]

				M. C. Granberry, J. B. Hawkins, and A. M. Franks Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure Am. J. Health Syst. Pharm., May 1, 2007; 64(9): 931 - 936. [Abstract] [Full Text] [PDF]

				M. Laplante, W. T. Festuccia, G. Soucy, Y. Gelinas, J. Lalonde, and Y. Deshaies Involvement of adipose tissues in the early hypolipidemic action of PPAR{gamma} agonism in the rat Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2007; 292(4): R1408 - R1417. [Abstract] [Full Text] [PDF]

				M. Laplante, W. T. Festuccia, G. Soucy, Y. Gelinas, J. Lalonde, J. P. Berger, and Y. Deshaies Mechanisms of the Depot Specificity of Peroxisome Proliferator-Activated Receptor {gamma} Action on Adipose Tissue Metabolism. Diabetes, October 1, 2006; 55(10): 2771 - 2778. [Abstract] [Full Text] [PDF]

				S. Franckhauser, S. Munoz, I. Elias, T. Ferre, and F. Bosch Adipose Overexpression of Phosphoenolpyruvate Carboxykinase Leads to High Susceptibility to Diet-Induced Insulin Resistance and Obesity Diabetes, February 1, 2006; 55(2): 273 - 280. [Abstract] [Full Text] [PDF]

				J R Porter and T G Barrett Monogenic syndromes of abnormal glucose homeostasis: clinical review and relevance to the understanding of the pathology of insulin resistance and {beta} cell failure J. Med. Genet., December 1, 2005; 42(12): 893 - 902. [Abstract] [Full Text] [PDF]

				J. K. Wolford, K. A. Yeatts, S. K. Dhanjal, M. H. Black, A. H. Xiang, T. A. Buchanan, and R. M. Watanabe Sequence Variation in PPARG May Underlie Differential Response to Troglitazone Diabetes, November 1, 2005; 54(11): 3319 - 3325. [Abstract] [Full Text] [PDF]

				Y. Miyazaki, E. De Filippis, M. Bajaj, E. Wajcberg, L. Glass, C. Triplitt, E. Cersosimo, L. J Mandarino, and R. A Defronzo Predictors of improved glycaemic control with rosiglitazone therapy in type 2 diabetic patients: a practical approach for the primary care physician The British Journal of Diabetes & Vascular Disease, January 1, 2005; 5(1): 28 - 35. [Abstract] [PDF]

				M. Berthiaume, H. Sell, J. Lalonde, Y. Gelinas, A. Tchernof, D. Richard, and Y. Deshaies Actions of PPAR{gamma} agonism on adipose tissue remodeling, insulin sensitivity, and lipemia in absence of glucocorticoids Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2004; 287(5): R1116 - R1123. [Abstract] [Full Text] [PDF]

				M A. Soroceanu, D. Miao, X.-Y. Bai, H. Su, D. Goltzman, and A. C Karaplis Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis J. Endocrinol., October 1, 2004; 183(1): 203 - 216. [Abstract] [Full Text] [PDF]

				Y. Miyazaki, A. Mahankali, E. Wajcberg, M. Bajaj, L. J. Mandarino, and R. A. DeFronzo Effect of Pioglitazone on Circulating Adipocytokine Levels and Insulin Sensitivity in Type 2 Diabetic Patients J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4312 - 4319. [Abstract] [Full Text] [PDF]

				I. Lemieux Energy Partitioning in Gluteal-Femoral Fat: Does the Metabolic Fate of Triglycerides Affect Coronary Heart Disease Risk? Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 795 - 797. [Full Text]

				H. Bays, L. Mandarino, and R. A. DeFronzo Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 463 - 478. [Full Text] [PDF]

				K. M. Ogilvie, R. Saladin, T. R. Nagy, M. S. Urcan, R. A. Heyman, and M. D. Leibowitz Activation of the Retinoid X Receptor Suppresses Appetite in the Rat Endocrinology, February 1, 2004; 145(2): 565 - 573. [Abstract] [Full Text] [PDF]

				M. Tiikkainen, R. Bergholm, A. Rissanen, A. Aro, I. Salminen, M. Tamminen, K. Teramo, and H. Yki-Jarvinen Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women Am. J. Clinical Nutrition, January 1, 2004; 79(1): 22 - 30. [Abstract] [Full Text] [PDF]

				M. Bajaj, S. Suraamornkul, P. Piper, L. J. Hardies, L. Glass, E. Cersosimo, T. Pratipanawatr, Y. Miyazaki, and R. A. DeFronzo Decreased Plasma Adiponectin Concentrations Are Closely Related to Hepatic Fat Content and Hepatic Insulin Resistance in Pioglitazone-Treated Type 2 Diabetic Patients J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 200 - 206. [Abstract] [Full Text] [PDF]

				S. Shadid and M. D. Jensen Effects of Pioglitazone Versus Diet and Exercise on Metabolic Health and Fat Distribution in Upper Body Obesity Diabetes Care, November 1, 2003; 26(11): 3148 - 3152. [Abstract] [Full Text] [PDF]

				T. Mae, H. Kishida, T. Nishiyama, M. Tsukagawa, E. Konishi, M. Kuroda, Y. Mimaki, Y. Sashida, K. Takahashi, T. Kawada, et al. A Licorice Ethanolic Extract with Peroxisome Proliferator-Activated Receptor-{gamma} Ligand-Binding Activity Affects Diabetes in KK-Ay Mice, Abdominal Obesity in Diet-Induced Obese C57BL Mice and Hypertension in Spontaneously Hypertensive Rats J. Nutr., November 1, 2003; 133(11): 3369 - 3377. [Abstract] [Full Text] [PDF]

				O. Gavrilova, M. Haluzik, K. Matsusue, J. J. Cutson, L. Johnson, K. R. Dietz, C. J. Nicol, C. Vinson, F. J. Gonzalez, and M. L. Reitman Liver Peroxisome Proliferator-activated Receptor {gamma} Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass J. Biol. Chem., September 5, 2003; 278(36): 34268 - 34276. [Abstract] [Full Text] [PDF]

				M. Bajaj, S. Suraamornkul, T. Pratipanawatr, L. J. Hardies, W. Pratipanawatr, L. Glass, E. Cersosimo, Y. Miyazaki, and R. A. DeFronzo Pioglitazone Reduces Hepatic Fat Content and Augments Splanchnic Glucose Uptake in Patients With Type 2 Diabetes Diabetes, June 1, 2003; 52(6): 1364 - 1370. [Abstract] [Full Text] [PDF]

				M. D. Aleo, G. R. Lundeen, D. K. Blackwell, W. M. Smith, G. L. Coleman, S. W. Stadnicki, and W. M. Kluwe Mechanism and Implications of Brown Adipose Tissue Proliferation in Rats and Monkeys Treated with the Thiazolidinedione Darglitazone, a Potent Peroxisome Proliferator-Activated Receptor-{gamma} Agonist J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1173 - 1182. [Abstract] [Full Text] [PDF]

				I. Pavo, G. Jermendy, T. T. Varkonyi, Z. Kerenyi, A. Gyimesi, S. Shoustov, M. Shestakova, M. Herz, D. Johns, B. J. Schluchter, et al. Effect of Pioglitazone Compared with Metformin on Glycemic Control and Indicators of Insulin Sensitivity in Recently Diagnosed Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1637 - 1645. [Abstract] [Full Text] [PDF]

				K. A. Virtanen, K. Hallsten, R. Parkkola, T. Janatuinen, F. Lonnqvist, T. Viljanen, T. Ronnemaa, J. Knuuti, R. Huupponen, P. Lonnroth, et al. Differential Effects of Rosiglitazone and Metformin on Adipose Tissue Distribution and Glucose Uptake in Type 2 Diabetic Subjects Diabetes, February 1, 2003; 52(2): 283 - 290. [Abstract] [Full Text] [PDF]

				M. Laplante, H. Sell, K. L. MacNaul, D. Richard, J. P. Berger, and Y. Deshaies PPAR-{gamma} Activation Mediates Adipose Depot-Specific Effects on Gene Expression and Lipoprotein Lipase Activity: Mechanisms for Modulation of Postprandial Lipemia and Differential Adipose Accretion Diabetes, February 1, 2003; 52(2): 291 - 299. [Abstract] [Full Text] [PDF]

				S. K. Gan, K. Samaras, C. H. Thompson, E. W. Kraegen, A. Carr, D. A. Cooper, and D. J. Chisholm Altered Myocellular and Abdominal Fat Partitioning Predict Disturbance in Insulin Action in HIV Protease Inhibitor-Related Lipodystrophy Diabetes, November 1, 2002; 51(11): 3163 - 3169. [Abstract] [Full Text] [PDF]

				S. M. Strowig, M. L. Aviles-Santa, and P. Raskin Comparison of Insulin Monotherapy and Combination Therapy With Insulin and Metformin or Insulin and Troglitazone in Type 2 Diabetes Diabetes Care, October 1, 2002; 25(10): 1691 - 1698. [Abstract] [Full Text] [PDF]

				O. Paulmyer-Lacroix, S. Boullu, C. Oliver, M.-C. Alessi, and M. Grino Expression of the mRNA Coding for 11{beta}-Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue from Obese Patients: An in Situ Hybridization Study J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2701 - 2705. [Abstract] [Full Text] [PDF]

				Y. Miyazaki, A. Mahankali, M. Matsuda, S. Mahankali, J. Hardies, K. Cusi, L. J. Mandarino, and R. A. DeFronzo Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2784 - 2791. [Abstract] [Full Text] [PDF]

				J. M. Poothullil, N. Mikhail, and S. E. Inzucchi Drug Therapy for Patients With Type 2 Diabetes JAMA, April 3, 2002; 287(13): 1645 - 1646. [Full Text] [PDF]

				G. J. Etgen, B. A. Oldham, W. T. Johnson, C. L. Broderick, C. R. Montrose, J. T. Brozinick, E. A. Misener, J. S. Bean, W. R. Bensch, D. A. Brooks, et al. A Tailored Therapy for the Metabolic Syndrome : The Dual Peroxisome Proliferator-Activated Receptor-{alpha}/{gamma} Agonist LY465608 Ameliorates Insulin Resistance and Diabetic Hyperglycemia While Improving Cardiovascular Risk Factors in Preclinical Models Diabetes, April 1, 2002; 51(4): 1083 - 1087. [Abstract] [Full Text] [PDF]

				Y. Miyazaki, M. Matsuda, and R. A. DeFronzo Dose-Response Effect of Pioglitazone on Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Diabetes Care, March 1, 2002; 25(3): 517 - 523. [Abstract] [Full Text] [PDF]

				A. B. Mayerson, R. S. Hundal, S. Dufour, V. Lebon, D. Befroy, G. W. Cline, S. Enocksson, S. E. Inzucchi, G. I. Shulman, and K. F. Petersen The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes Diabetes, March 1, 2002; 51(3): 797 - 802. [Abstract] [Full Text] [PDF]

				Y. Arad, D. Newstein, F. Cadet, M. Roth, and A. D. Guerci Association of Multiple Risk Factors and Insulin Resistance With Increased Prevalence of Asymptomatic Coronary Artery Disease by an Electron-Beam Computed Tomographic Study Arterioscler. Thromb. Vasc. Biol., December 1, 2001; 21(12): 2051 - 2058. [Abstract] [Full Text] [PDF]

				C. J. de Souza, M. Eckhardt, K. Gagen, M. Dong, W. Chen, D. Laurent, and B. F. Burkey Effects of Pioglitazone on Adipose Tissue Remodeling Within the Setting of Obesity and Insulin Resistance Diabetes, August 1, 2001; 50(8): 1863 - 1871. [Abstract] [Full Text] [PDF]

				Y. Miyazaki, A. Mahankali, M. Matsuda, L. Glass, S. Mahankali, E. Ferrannini, K. Cusi, L. J. Mandarino, and R. A. DeFronzo Improved Glycemic Control and Enhanced Insulin Sensitivity in Type 2 Diabetic Subjects Treated With Pioglitazone Diabetes Care, April 1, 2001; 24(4): 710 - 719. [Abstract] [Full Text]

				H. Yki-Järvinen Combination Therapies With Insulin in Type 2 Diabetes Diabetes Care, April 1, 2001; 24(4): 758 - 767. [Full Text]

				A. Katsuki, Y. Sumida, E. C. Gabazza, S. Murashima, M. Furuta, R. Araki-Sasaki, Y. Hori, Y. Yano, and Y. Adachi Homeostasis Model Assessment Is a Reliable Indicator of Insulin Resistance During Follow-up of Patients With Type 2 Diabetes Diabetes Care, February 1, 2001; 24(2): 362 - 365. [Abstract] [Full Text]

				H. E. Lebovitz, J. F. Dole, R. Patwardhan, E. B. Rappaport, and M. I. Freed Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 280 - 288. [Abstract] [Full Text]

				E. Arioglu, J. Duncan-Morin, N. Sebring, K. I. Rother, N. Gottlieb, J. Lieberman, D. Herion, D. E. Kleiner, J. Reynolds, A. Premkumar, et al. Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes Ann Intern Med, August 15, 2000; 133(4): 263 - 274. [Abstract] [Full Text] [PDF]

				O. P. Ganda Lipoatrophy, Lipodystrophy, and Insulin Resistance Ann Intern Med, August 15, 2000; 133(4): 304 - 306. [Full Text] [PDF]

				J. Berger, M. Tanen, A. Elbrecht, A. Hermanowski-Vosatka, D. E. Moller, S. D. Wright, and R. Thieringer Peroxisome Proliferator-activated Receptor-gamma Ligands Inhibit Adipocyte 11beta -Hydroxysteroid Dehydrogenase Type 1 Expression and Activity J. Biol. Chem., April 13, 2001; 276(16): 12629 - 12635. [Abstract] [Full Text] [PDF]